Precautions and safety tips when using eflornithine (IWILFIN)

Eflornithine (IWILFIN) is an oral fluoropyrimidine anti-tumor drug, mainly used to treat colorectal cancer, gastric cancer and other solid tumors. Its mechanism of action is to inhibit the proliferation of cancer cells by inhibiting thymidylate synthase and interfering with DNA synthesis. During use, medical instructions must be strictly followed to ensure efficacy and reduce the risk of adverse reactions.

First of all, the dosage and time of taking the medicine must be strictly adhered to the doctor's prescription. Eflornithine has certain dose-dependent toxicity, and excessive use may lead to severe bone marrow suppression, gastrointestinal adverse reactions, or cardiotoxicity. Patients should undergo regular blood routine, liver and kidney function and electrocardiogram examinations during the medication period in order to detect potential risks and adjust the dose in a timely manner.

Secondly, patients need to pay attention to drug interactions. Eflornithine may interact with certain drugs, such as oral anticoagulants, some antiepileptic drugs, and other chemotherapy drugs, affecting efficacy or increasing toxicity. Therefore, patients should truthfully inform their doctors about all the drugs and health care products they are using during use, and avoid taking combined drugs on their own.

Finally, safety management should be paid attention to in daily life. Eflornithine may cause nausea, vomiting, diarrhea, oral ulcers and other uncomfortable reactions. Patients can relieve symptoms through a reasonable diet, adequate fluids and proper rest. At the same time, when fever, bleeding, severe fatigue or other abnormal symptoms occur, you should seek medical treatment immediately to avoid delaying treatment. By strictly complying with medication instructions and safety management, eflornithine can minimize the risk of adverse reactions while ensuring efficacy.

Reference link:https://www.drugs.com